SigOnco Named to 2024 Greater Bay Area Top 50 Biotech Innovators Amid IPO Filing

Recently, the Greater Bay Area Biotechnology Innovation Summit and the 7th Greater Bay Area Biotechnology Innovation Enterprises Top 50 Selection successfully concluded in Guangzhou. SIGNET has been listed among the "Top 50 Biotechnology Innovation Enterprises in the Greater Bay Area" for four consecutive years, receiving the "Rising Star Enterprise" award in 2024.

This event was hosted by Zhongchuang Industry Research Institute, organized by Guangdong Medical Valley, and co-organized by China Merchants Bank Guangzhou Branch. It aims to further promote the cluster development of the biotechnology industry in the Greater Bay Area and create a vibrant and highly competitive life sciences industrial cluster.

SIGNET is the first company globally to leverage organoids and AI-driven models to accelerate the development of innovative targeted drugs. The company’s globally first targeted drug for diffuse gastric cancer, SIGX1094, developed based on this platform, has successfully entered Phase I clinical trials. This platform empowers the entire new drug development process from target discovery to efficacy validation, bringing disruptive innovation to the entire drug R&D process. It has been successfully selected as one of the top 50 biotech innovation companies in the Guangdong-Hong Kong-Macao Greater Bay Area in 2024, showcasing its outstanding achievements in advancing biopharmaceutical innovation.

SIGNET is the first cancer innovative targeted drug research and development company in China based on organoid disease models + AI. It was initially founded on the Harvard University campus and landed in Shenzhen by the end of 2020, completing financing and project funding of nearly 220 million yuan. The company currently has four drug pipelines. The first pipeline is developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer, which has successively obtained IND approval from the U.S. FDA and China NMPA, and received orphan drug designation from the U.S. FDA. It has now entered Phase I clinical trials.

SIGNET is not only the phonetic translation of Signet but also adheres to the vision of "Full of Hope, Studying Things to Gain Knowledge." The company leverages organoid disease models that closely resemble patients' genomic characteristics for critical roles in drug efficacy evaluation and new target discovery. Combined with AI-powered screening, synthesis, and optimization of small-molecule compounds, SIGNET develops first-in-class innovative targeted drugs. The company has a 1200㎡ R&D facility and a 500㎡ experimental animal housing area. SIGNET's organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.